Neurocrine Biosciences announces regulatory approval of Dysval (valbenazine) for the treatment of tardive dyskinesia in Japan

Neurocrine Biosciences

29 March 2022 - Neurocrine Biosciences today announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation, has obtained regulatory approval of Dysval (valbenzine) 40 mg capsules for the treatment of tardive dyskinesia from the Japanese Ministry of Health, Labour and Welfare on 28 March 2022.

Read Neurocrine Biosciences press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Japan